5-Amino-1MQ vs AOD 9604: do they actually do the same thing?

What did @kempcore.hq actually say?

The creator argued that 5-Amino-1MQ and AOD-9604 are "totally different lanes" with distinct mechanisms. 5-Amino-1MQ was framed as a cellular energy compound that raises NAD+ levels and supports metabolism, mental energy, and recovery. AOD-9604 was described as a fat-targeting peptide that breaks down stored fat, blocks new fat storage, and may support joint comfort without acting like a growth hormone secretagogue.

They used a car analogy: 5-Amino-1MQ upgrades the engine, AOD-9604 adjusts the air-to-fuel mixture. Both were said to only work when training and nutrition are already solid. The creator noted that "human data is still catching up" on 5-Amino-1MQ, and recommended looping in a provider. They also compared AOD-9604 to "Tessamarillin" (almost certainly meaning Tesamorelin), distinguishing it from a full growth hormone secretagogue.

Does the science back this up?

The core mechanistic claims here are mostly grounded in real pharmacology, but the evidence base is thin and the creator glosses over just how thin it actually is. The distinction between the two compounds is legitimate. The confidence around clinical outcomes is not fully earned.

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that breaks down NAD+ precursors. By inhibiting NNMT, the compound theoretically raises intracellular NAD+ availability. A 2021 study by Neelakantan et al. in Nature Communications showed NNMT inhibition reduced fat mass in obese mice and improved metabolic markers. That is a mouse study. There is no published randomized controlled trial in humans on 5-Amino-1MQ specifically. The claim that it supports "sharp mental energy" has essentially no direct human evidence behind it.

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically residues 176-191, modified with an additional tyrosine. A 2001 study by Heffernan et al. in Journal of Endocrinology found lipolytic activity in rodent models. Human trials by Metabolic Pharmaceuticals (who funded most of the research) showed modest effects on body fat in some trials but failed to achieve regulatory approval. The joint-comfort claim the creator makes has even less backing in the published literature.

What did they get wrong (or right)?

They got the basic mechanistic distinction right. These compounds do work through different pathways. Giving credit where it is due: framing 5-Amino-1MQ as a compound where "human data is still catching up" is honest, and more than a lot of peptide content creators will say out loud.

The joint benefit claim for AOD-9604 is where things get slippery. The creator says "a lot of people also notice their joints feel a little better on it," which is anecdotal and unsupported by controlled data. This sounds plausible because hGH itself has connective tissue effects, but AOD-9604 is specifically engineered to lack hGH receptor binding. The mechanism for a joint benefit simply does not follow from the pharmacology.

The "Tessamarillin" reference is a mispronunciation of Tesamorelin, which is an FDA-approved GHRH analog (brand name Egrifta) indicated for HIV-associated lipodystrophy. Comparing AOD-9604 to Tesamorelin is a reasonable reference point, but conflating or mispronouncing a brand-name FDA-approved drug in a peptide coaching context is the kind of casual error that matters in regulated spaces.

The personal anecdote framing, saying "I've used it" and "it's been a reliable tool," is not medical evidence. It is marketing. That distinction matters when 10,000+ viewers may take it as clinical validation.

What should you actually know?

If you are considering either compound, the regulatory and evidence landscape matters more than the analogy. Neither compound is FDA-approved for the uses described here. 5-Amino-1MQ is not a peptide at all, it is a small molecule. AOD-9604 was studied for obesity and failed to achieve FDA approval despite industry-funded trials.

Both compounds are available through compounding pharmacies in the U.S. under specific circumstances, but "available" does not mean "proven safe and effective at the doses and contexts described in a TikTok video." The known side effect profile for 5-Amino-1MQ in humans is genuinely limited because large-scale human trials do not exist yet. Headaches and GI upset, as the creator mentions, come mostly from user reports and small observational data, not controlled trials.

AOD-9604 has a longer human trial history, with Heffernan and colleagues publishing across the early 2000s, but those trials showed modest and inconsistent effects. The compound's safety profile in short-term use appears reasonable based on available data, but long-term effects are not well characterized. Anyone combining these compounds with other metabolic interventions should have a provider actively monitoring relevant biomarkers, not just a peptide coach with a sourcing checklist.